OTLCOncotelic Therapeutics, Inc.

About Oncotelic Therapeutics, Inc. (OTLC)

Oncotelic Therapeutics, Inc. (OTLC) is a Biotechnology company headquartered in Agoura Hills, CA, United States whose shares trade over-the-counter on the OTCQB tier.

Oncotelic Therapeutics, Inc. (OTLC) are developing three lines of therapeutics. 1) Oncology/Virology - we are developing OT-101 (TGF-beta antisense/ Artemisinin).against certain oncology indications and viral infections. The program is being funded by our partner GMP through a JV that we are intend to take IPO. In addition, we are developing our VDA agents (Oxi4503/CA4P) various tumors, including three rare pediatric tumors (DIPG, Melanoma, and AML). 2) AL-101 (intranasal-apomorphine) for the treatment of Parkinson Disease, Erectile Dysfunction not responding to PDE5 inhibitor, and Female Sexual Dysfunction. 3) Animal health product including oncology (CA4P and Artemishas).

Products and services

Developer of therapies for Oncology and Virology

OTLC key facts

Ticker symbol

OTLC

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Agoura Hills, CA, United States

Country of incorporation

US

Employees

22

Estimated market cap

$20.32M (as of Apr 10, 2025)

Shares outstanding

407,273,147

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Oncotelic Therapeutics, Inc. leadership

• Vuong Trieu — CEO
• Amit Bhupendra Shah — CFO
• Seymour Fein — CMO
• Saran Saund — CBO

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with O